In this MinuteCE, Drs. Jose Rubio and Sunny Tang examine the recurrent course of bipolar disorder, predictors of relapse, and the clinical burden of residual mood symptoms and cognitive impairment. They discuss limitations of current pharmacologic therapies and review dopaminergic and cholinergic neurocircuitry, with emphasis on M1 and M4 muscarinic receptors as potential therapeutic targets for mania, psychosis, and cognitive dysfunction. The discussion also examines ongoing phase 3 BALSAM-1 and BALSAM-2 trials of xanomeline-trospium for acute mania and mania with mixed features, as well as its potential role in the bipolar disorder treatment algorithm.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
CME included with membership
| Free Registration | Free |
| Tufts-Affiliated HCP - Early Bird (by 10/5/26) | $75 |
| Tufts-Affiliated HCP - Standard | $175 |
| Trainees & Allied Health - Early Bird (by 10/5/26) | $75 |
| Trainees & Allied Health - Standard | $175 |
| Physicians - Early Bird (by 10/5/26) | $150 |
+3 more tiers
Collected from the provider’s public pages · source
Specialties served/covered
- Advanced Heart Failure & Transplant Cardiology
- Allergy & Clinical Immunology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Diagnostic Radiology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- General & Adult Psychiatry
- General Pediatrics
- Gynecologic Oncology
- Head & Neck Surgery
- Hematology
- Maternal-Fetal Medicine
- Medical Genetics & Genomics
- Medical Oncology
- Mood & Anxiety Disorders
- Nephrology
- Neurology
- Neuromuscular Medicine
- Neuroradiology
- Obstetrics & Gynecology
- Ophthalmology
- Pediatric Neurology
- Psychopharmacology
- Psychotic Disorders
- Pulmonary Disease
- Radiation Oncology
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Transplant Hepatology
- Urological Oncology
- Vascular Neurology
- Cardio-Vascular
- Cross-Specialty
- ENT & Head Neck
- GI & Liver
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Board review / self-assessment
- Credit · Up to 0.5 credits
- Commercial Support
-
ReleasedSep 18, 2026
-
Last day to claim creditSep 19, 2027 11 months left
-
Global Learning Collaborative Muscarinic Therapies as a Catalyst for Change: Addressing Clinical Inertia in Schizophrenia Care
-
Global Learning Collaborative Chairperson s Perspective: Incorporating Novel Treatment Options for Schizophrenia Into Clinical Practice Overcoming Clinical Inertia
-
Global Learning Collaborative From Inertia to Action: Integrating Muscarinic Therapies into Schizophrenia Practice
